Clevudine

This image is provided by the National Library of Medicine.

WikiDoc Resources for Clevudine
Articles
Most recent articles on Clevudine Most cited articles on Clevudine Review articles on Clevudine Articles on Clevudine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Clevudine Images of Clevudine Photos of Clevudine Podcasts & MP3s on Clevudine Videos on Clevudine
Evidence Based Medicine
Cochrane Collaboration on Clevudine Bandolier on Clevudine TRIP on Clevudine
Clinical Trials
Ongoing Trials on Clevudine at Clinical Trials.gov Trial results on Clevudine Clinical Trials on Clevudine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Clevudine NICE Guidance on Clevudine NHS PRODIGY Guidance FDA on Clevudine CDC on Clevudine
Books
Books on Clevudine
News
Clevudine in the news Be alerted to news on Clevudine News trends on Clevudine
Commentary
Blogs on Clevudine
Definitions
Definitions of Clevudine
Patient Resources / Community
Patient resources on Clevudine Discussion groups on Clevudine Patient Handouts on Clevudine Directions to Hospitals Treating Clevudine Risk calculators and risk factors for Clevudine
Healthcare Provider Resources
Symptoms of Clevudine Causes & Risk Factors for Clevudine Diagnostic studies for Clevudine Treatment of Clevudine
Continuing Medical Education (CME)
CME Programs on Clevudine
International
Clevudine en Espanol Clevudine en Francais
Business
Clevudine in the Marketplace Patents on Clevudine
Experimental / Informatics
List of terms related to Clevudine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings. It is a nucleoside analog.